NEWS RELEASE

23rd August 2016, Hyderabad, India

Aurobindo Pharma Ltd Q1 FY16-17 financial results ending 30th June 2016

Company has adopted Indian Accounting Standards (Ind AS) from 1st April 2016 and hence the financials are prepared in accordance with the reporting structure prescribed by Section 133 of the Company's Act 2013. For comparison purpose Q1 FY15-16 financials are also restated as per Ind AS.

Amount in INR Cr	Q1 FY16-17	Q1 FY15-16	% Change
Consolidated Net Operating Income*	3,725.9	3,298.9	*12.9*
EBITDA before Forex	889.0	725.0	*22.6*
EBITDA %	23.9%	22.0%	
PBT	785.0	634.0	*23.8*
PAT (after JV share, minority interest and OCI)	584.6	471.3	*24.0*

*Net of excise duty, OCI: Other Comprehensive Income

Consolidated Performance for Q1 FY16-17 on YoY basis:

- Total Operating Income up by 12.9% to INR 3,725.9 Cr vs INR 3,298.9 Cr
- Operating Profit (EBIDTA) before Forex up 22.6% to INR 889.0 Cr vs INR 725.0 Cr; EBITDA margin at 23.9%
- PBT up by 23.8% to INR 785.0 Cr vs INR 634.0 Cr
- PAT after JV share, minority interest and OCI up by 24.0% to INR 584.6 Cr vs INR 471.3 Cr
- Basic & Diluted EPS is INR 9.99 per share
- Formulations business registered a growth 15.9% at INR 3,032 Cr (80.5% of Gross Sales)
- API business registered 1.6% growth at INR 734.5 Cr (19.5% of Gross Sales)
- Received 13 final approvals and 7 tentative approvals for the ANDAs from USFDA

Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said:

"The quarter started with a double digit growth Year on Year on the back of overall business performance. With focus on execution and capability enhancements we continue to progress on specialty generics for a sustained long term growth."

Operational Performance (Consolidated):

Gross Sales (Amt in INR Cr)	Q1 FY16-17	Q1 FY15-16	% Chg (YoY)
Formulations			
USA	1,703.9	1,413.7	*20.5*
Europe	831.2	741.8	*12.1*
Emerging Markets	194.0	164.9	*17.6*
ARV	303.0	295.3	*2.6*
Total Formulations	**3,032.1**	**2,615.7**	***15.9***
Active Pharmaceuticals Ingredients (API)			
Betalactum	495.0	477.8	*3.6*
Non Betalactum	239.6	245.1	*(2.3)*
Total API	**734.5**	**722.9**	***1.6***
Consolidated Gross Sales	**3766.6**	**3338.5**	***12.8***
Dossier Income	0.0	0.0	
Less: Excise Duty	40.7	39.7	
Operating Income (net of excise duty)	3,725.9	3,298.9	*12.9*

The formulations business contributed 80.5% to the total revenues and witnessed 15.9% YoY growth during the quarter. The broad base growth across all the markets led to an increase in the formulations revenue.

US Formulations: The business contributed 45% to the gross sales and witnessed 20.5% growth YoY in Q1 FY16-17. This is due to the new launches in the oral and injectable segment

EU Formulations: Contributed 22% to the gross sales and registered 12.1% growth YoY during the quarter. The acquired business continue to see profitability during the quarter.

ARV formulations: The ARV business was flat during the quarter vs the same quarter previous year with revenue contribution of 8% to gross sales.

Emerging Markets formulations: The Emerging Markets formulation business constitutes 5.1% of the gross sales of the company. The business registered 17.6% growth YoY during Q1 FY16-17.

API: The Active Pharmaceuticals Ingredients business contributed 19.5% to the gross sales. The company sells API to domestic as well as the global market.

During the quarter, the sales to the international markets stood at INR 3,372.3 Cr and the domestic sales were at INR 394.3 Cr representing 90% and 10% respectively.

Global Regulatory Filings:

During Q1 FY16-17, the company filed 5 ANDA with USFDA including 3 in the Oral Category and 2 in the Injectable category. The company during the period received 20 ANDA approvals from USFDA including 13 Final approvals and 7 tentative approvals. On a cumulative basis the company received 269 approvals from USFDA including 41 tentative* approvals.

*Tentative approvals include 21 ANDAs approved under PEPFAR.

Filings	Q1 FY16-17	Cumulative Filings as on 30th June 2016
ANDAs (including filings made from Aurobindo USA)	5	403
DMFs (including filings made from AuroNext and AuroPeptide)	1	206
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	111	2,816
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	22	2,544

For Europe Formulations, as on 30th June 2016 additional 1,641 MAs have been transferred from Actavis

USFDA approvals received in Q1 FY16-17:

Final Approvals

1. Polymyxin B for Inj (Gx Polymyxin B®) 500,000 Units/Vial — Anti-Infective
2. Esomeprazole Magnesium DR Cap (Gx Nexium®) 20mg & 40mg — Gastrointestinal
3. Amlodipine and Valsartan Tab (Gx Exforge®) 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg & 10mg/320mg — CVS
4. Oxymorphone Hydrochloride Tab (Gx Opana®) 5 &10mg — Controlled Substance
5. Famotidine Tab (OTC) (Gx Pepcidac®) 10 & 20mg — Gastrointestinal
6. Lacosamide Tab (FTF) (Gx Vimpat®) 50, 100, 150 & 200mg — Controlled Substance
7. Fenofibrate Tab USP (Gx Tricor®) 48 & 145mg — CVS
8. Zolmitriptan Tab (Gx Zomig®) 2.5 & 5mg — Pain Relief
9. Hydromorphone Hydrochloride Tab (Gx Dilaudid®) 2,4 & 8mg — Controlled Substance
10. Bupivacaine Hydrochloride Inj (Gx Marcaine®) 0.25% (2.5 mg/mL) & 0.5% (5 mg/mL) - 50mL — CNS
11. Methocarbamol Inj (Gx Robaxin®) 1,000mg/10mL (100mg/mL) — CNS
12. Hydrocodone and Ibuprofen Tab (Gx Vicoprofen®) 7.5/200mg — Controlled Substance
13. Amiodarone Hydrochloride Tab (Gx Cordarone®) 200mg — CVS

Tentative Approvals

1. Olmesartan Medoxomil Tab (Gx Benicar®) 5, 20 & 40mg — CVS
2. Tadalafil Tab (Gx Cialis®) 2.5, 5, 10 & 20mg — CVS
3. Fesoterodine Fumarate ER Tab (FTF) (Gx Toviaz®) 4 & 8mg — Genitourinary Drugs
4. Dalfampridine ER Tab (FTF) (Gx Ampyra®) 10 mg — CNS
5. Pregabalin Cap (Gx Lyrica®) 25, 50, 75, 100, 150, 200, 225 & 300mg — CNS
6. Omeprazole Magnesium DR Tab (OTC) (Gx Prilosec®) 20.6mg — Gastrointestinal
7. Efavirenz Tab (Gx Sustiva®) 600mg — ARV

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Investor Relations
Deepika Gupta Padhi
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd.Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com (Rs. In lakhs)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2016

	Particulars	Consolidated	
		Three months ended	
		30.06.2016	30.06.2015
		Unaudited	Unaudited Refer note 3 and 4
1	**Income from operations**		
	(a) Net sales/income from operations (Net of excise duty)	**366,391**	324,229
	(b) Other operating income	**6,199**	5,664
	Total income from operations (net)	**372,590**	329,893
2	**Expenses**		
	(a) Cost of material consumed	**127,516**	119,885
	(b) Purchase of stock-in-trade	**40,894**	32,252
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	**(4,713)**	(901)
	(d) Employee benefits expense	**43,208**	36,119
	(e) Depreciation and amortisation expense	**10,624**	8,899
	(f) Other expenses	**76,789**	70,033
	Total expenses	**294,318**	266,287
3	**Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)**	**78,272**	63,606
4	Other Income	**1,589**	2,937
5	**Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)**	**79,861**	66,543
6	Finance costs (refer note 7)	**2,064**	2,083
7	Foreign exchange (Gain)/Loss (refer note 7)	**(704)**	1,058
8	**Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-**	**78,501**	63,402
9	Exceptional item	**-**	-
10	**Profit /(Loss) from ordinary activities before tax (8-9)**	**78,501**	63,402
11	Tax expense/(credit)	**20,084**	16,343
12	**Net Profit /(Loss) for the period (10-11)**	**58,417**	47,059
13	Share of(loss)/profit of joint ventures	**73**	133
14	Minority Interest	**(6)**	(53)
15	**Net Profit/(Loss) after taxes, minority interest and share of loss/profit of joint ventures**	**58,496**	47,245
16	Other Comprehensive income	**(36)**	(115)
17	**Total Comprehensive income**	**58,460**	**47,130**
18	Paid-up Equity Share Capital (Face value Re. 1 per share)	**5,852**	2,920
19	Earnings per share of Re.1/- each (not annualised)		
	(a) Basic	**9.99**	8.09
	(a) Diluted	**9.99**	8.09

NOTES:

1 These consolidated unaudited financial results relate to Aurobindo Pharma Limited ('the Holding Company'), its Subsidiaries (together constitute 'the Group') and Joint Ventures and are prepared by applying Ind AS 110 - "Consolidated Financial Statements" and Ind AS 28 - "Investments in Associates and Joint ventures".

2 The Group and joint ventures have adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is April 01, 2015 and accordingly, these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.

3 The above consolidated financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on August 23, 2016. A limited review of the consolidated financial results for the quarter ended June 30, 2016 have been carried out by the Statutory Auditors. The financial results and other financial information for the quarter ended June 30, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide a true and fair view of the Company's affairs.

4 There is a possibility that these quarterly financial results may require adjustment before constituting the final Ind AS financial statements as of and for the year ending 31 March 2017 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.

5 The reconciliation of Net profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	3 months ended June 30, 2015
Net profit under prevous GAAP	43,244
Impact on deferred tax (including on unrealised intragroup profits on inventories)	2,292
Impact of foreign currency exchange differences	1,567
Difference in measurement of employee benefit expenses	191
Other Ind AS adjustments	(49)
Net profit for the priod under Ind AS	47,245

6 The Group has only one reportable segment namely 'Pharmaceuticals'.

7 Foreign exchange (gain)/loss for consolidated results includes exchange difference of Rs.3,652 lakhs and Rs.6,424 lakhs for three months ended June 30, 2016 and June 30, 2015 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.

8 The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.

9 The Company on July 22, 2015, had allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company had increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each. The earnings per share has been adjusted for bonus issue for previous period presented in accordance with Ind AS 33, Earning per share.

10 During the quarter (i) Auro AR LLC, a step down subsidiary was incorporated w.e.f May 2, 2016 as a Special Purpose Entity, (ii) Aurobindo Pharma USA LLC, a step down subsidiary was incorporated w.e.f April 14, 2016.

By Order of the Board

Place: Hyderabad
Date : August 23, 2016

www.aurobindo.com

N.Govindarajan
Managing Director